|Bid||1.21 x 3000|
|Ask||1.36 x 1800|
|Day's Range||1.26 - 1.30|
|52 Week Range||0.96 - 2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.86|
Novavax (NVAX) generated revenue of $10.77 million in the second quarter compared to $6.73 million in the comparable period in 2017. The increase in the company’s revenue resulted from a $2 million increase in the Bill and Melinda Gates Foundation grant revenue due to higher enrolment in Novavax’s Prepare trial and an additional $2 million from increased activities from Novavax AB. The general and administrative expenses incurred by Novavax decreased from $8.94 million in the second quarter of 2017 to $8.22 million in the second quarter of 2018.
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Novavax Delivers on Key Milestones Supporting its 2018 Objectives. Company to Host Conference Call Today at 4:30 pm ET. GAITHERSBURG, Md., Aug. 08, 2018-- Novavax, Inc. today announced its financial results ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novavax, Inc. (NASDAQ: NVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
GAITHERSBURG, Md., Aug. 01, 2018-- Novavax, Inc. today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August ...
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...
Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season. Influenza is an infectious disease that causes illness in humans, ranging from mild to life-threatening symptoms or death. Largely in part due to infection by unique strains of influenza for which most people have not developed protective antibodies, serious illness occurs in susceptible populations (such as the elderly and very young) as well as the general population.
Novavax (NVAX) completed a public offering of ~34.9 million shares of its common stock in April. Through this offering, the company raised ~$54 million. In the first quarter, Novavax sold 15.7 million of its common shares, raising $32.3 million in net proceeds. Its number of outstanding shares is expected to rise to ~400 million from ~262 million between fiscal 2015 and fiscal 2019.
Novavax (NVAX) generates revenue in the form of grants from the Bill and Melinda Gates Foundation (or BMGF) for the development of its RSV F (respiratory syncytial virus fusion protein) vaccine for infants via maternal immunization. During the first quarter of fiscal 2018, the company’s revenue rose YoY (year-over-year) to $9.7 million from $5.7 million. The BMGF awarded an $89.1 million grant to Novavax in 2015, of which the company has recognized $51 million so far.
In addition to developing RSV (respiratory syncytial virus) and influenza vaccines, Novavax (NVAX) is also developing immune-stimulating saponin-based adjuvants through its Swedish subsidiary, Novavax AB. Its lead adjuvant, Matrix-M, has been shown to enhance immune response and has been well tolerated in multiple clinical trials.
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market. Of the eight analysts covering Novavax, four have recommended “buy” or a higher rating, three have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.4, and their target price is $3.93, implying a 144% upside based on its June 13 closing price of $1.61. Of the 20 analysts covering Merck (MRK), 15 have recommended “buy” or a higher rating, and five have recommended “hold.” Their mean rating for the stock is 2, and their target price is $69.02.
NanoFlu TM Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine NanoFlu demonstrates significantly improved immune responses against a panel of ...